x

A research alliance to accelerate the development of new therapeutics

In January 2024, Washington University in St. Louis (WashU) and healthcare investment firm, Deerfield Management, announced a research and development collaboration to help bring next-generation therapeutics to market.

Through a newly launched company called VeritaScience, LLC, Deerfield has committed up to $130 million over a 10-year period and may provide WashU scientists with both funding and functional expertise to advance biomedical research.

Washington University in St. Louis is among the world’s leaders in teaching, research, patient care and service to society. WashU is distinctive in its purpose-driven scholarship across a wide range of academic disciplines, its highly supportive residential undergraduate experience, and its world-class research enterprise, which addresses scientific, social, economic and medical challenges locally, nationally and globally.

WashU draws students and faculty to St. Louis from all 50 states and more than 100 countries. The total student body is over 17,000 and approximately 4,300 faculty teach in eight schools: School of Medicine; McKelvey School of Engineering & Applied Science; Arts & Sciences; Brown School; Olin Business School; Sam Fox School of Design & Visual Arts; School of Law; and University College. The university offers more than 90 programs and some 1,500 courses leading to bachelor's, master's and doctoral degrees in a broad spectrum of traditional and interdisciplinary fields, with additional opportunities for minor concentrations and individualized programs. Twenty-six Nobel laureates have been associated with Washington University.

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,800 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools, has grown more than 40% in the last six years and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,800 faculty physicians practicing at over 65 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children’s hospitals of BJC HealthCare.

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please visit www.deerfield.com.

Timeline for Proposal Submissions

Proposal Sourcing

Faculty work with WashU’s OTM or BD department to outline their idea.

Scientific Review

Your proposal will be reviewed by members of our scientific team.

Full Proposal

If your idea is selected for further evaluation, you will be invited to submit a full proposal.

Investment Evaluated

Your proposal will be carefully evaluated for funding by Deerfield’s investment team.

For more information on proposal submissions, please reach out to the WashU Medicine business development team.

Mark Van Horn. Senior Director of Business Development, markv@wustl.edu

Oscar Diaz Ruiz, Business Development Project Manager, doscar@wustl.edu

Have more specific questions?

Contact the VeritaScience team.